ottobock.

Omo Neurexa



Clinical Study Summaries

This document summarizes clinical studies conducted with the Omo Neurexa. The included studies were identified by a literature search made on PubMed and within the journals NeuroRehabilitation, Or-thopädie-Technik and Neurologie & Rehabilitation.

ottobock.

Table of content:

1 Overview table p 3
2 Summaries of categoriesp 4-21
Biomechanics – Gait analysis p 5
X-Ray p 8
EMGp 11
Functional tests
Clinical effectsp 16
Satisfactionp 19
3 Summaries of individual studies
Hesse et al. 2013p 23
Hesse et al. 2009p 27
Hesse et al. 2008
4 Copyrightp 32

1 Overview table

The summaries are organized in three levels depending on the detail of information. The overview table (Level 1) lists all the relevant publications dealing with a particular product (topic) as well as researched categories (e.g. gait analysis, clinical effects, satisfaction, etc). By clicking on underlined categories, a summary of all the literature dealing with that category will open (Level 2).

For those interested to learn more about individual studies, a summary of the study can be obtained by clicking on the relevant reference (Level 3).

		Category							
Refere	nce		Functions and Activities						
Author	Year	Biomechanics – Static measures	X-Ray EMG Eunctional tests Clinical attacts						
<u>Hesse</u>	2013		x	x	x	x	x	x	
<u>Hesse</u>	2009		x	x	x	x	x	x	
<u>Hesse</u>	2008			x			x	x	
Total number: 3 0		0	2	3	2	2	3	3	


2 Summaries of categories

On the following pages you find the summary of categories researched in several studies (e.g. gait analysis, clinical effects, satisfaction, etc.). At the end of the summary you will find a list of reference studies contributing to the content of the particular summary.

Biomechanics – Gait analysis

Major Findings	With Omo Neurexa compared to no orthotic treatment:				
	→ Significantly more symmetric gait				
	 7.5% prolonged hemiparetic side stance phase (Hesse et al. 2013) 6.9% increased stance symmetry ratio (Hesse et al. 2013) 				
	- 17% reduction in relative double support phase (Hesse et al. 2009)				
	→ Tendency towards a greater stride length and towards a lower cadence (Hesse et al. 2009)				
	→ Other gait relating aspects:				
	- 70% of patients reported that they felt more secure during transfer tasks and mobility (Hesse et al. 2009)				
	- Protection of the paretic arm leads to a better concentration on gait rehabil- itation (Hesse et al. 2008)				
	- Improved patient- and therapist-reported activity level and performance in mobility related activities of daily living (Hesse et al. 2013)				

The instrumented gait analysis showed that the patients walked more symmetrically while wearing the Omo Neurexa



(Hesse et al. 2013; Asterisks indicate significant group differences with ++= p< 0.05)

Clinical Relevance	Faster and more efficient gait is an important goal of rehabilitation after stroke, es- pecially for the chronic stroke patient who often continues to be limited in daily activ- ities by slow, insecure gait. (Jonsdottir et al. 2007)						
	For lower extremities, the most important function is ambulation. It influences the mobility grade of the subject, participation and, therefore, general quality of life. Furthermore, a natural gait pattern is favorable as it prevents the sound side from higher or inappropriate loading due to compensatory movements. Gait asymmetries can contribute to secondary diseases such as osteoarthritis.						
	Safety aspects while walking are highly relevant to the patients. Since the fear of falling can have a negative impact on activities of daily living as well as on participation, perceived safety is regarded as an important factor for quality of life.						
	Cognitive demand of walking is investigated to determine how much attention has to be paid to walking. This is important because many activities in daily life are per- formed simultaneously (e.g. walking and talking on the phone).						
	The Omo Neurexa aims to repositioning the subluxated shoulder joint in the right position and thus reducing pain and improving gait.						
Summary	Three studies evaluated the effectiveness of the Omo Neurexa:						
	Instrumented gait analysis was performed with and without the Omo Neurexa by Hesse et al. (2009 and 2013). Initially, patients performed the 10-m test twice with- out any instrumentation, in order to determine their self-selected walking velocity. During the subsequent instrumented gait analysis with and without the orthosis, the patients were instructed to walk at their self-selected speed, cued by a metronome. Gait analysis was performed on a floor 100-m long walk way. Limb-dependent cycle parameters were averaged over 30s, and normalized with respect to the gait cycle (= 100%). Symmetry ratios were calculated for stance and swing durations (dura- tion of the left-side divided by that of the right if the duration of the left was shorter, or vice versa).						
	During the instrumented gait analysis a more symmetric and dynamic gait pattern could be observed when walking with the Omo Neurexa (Hesse et al. 2009, Hesse et al. 2013) and an improvement in activity level and performance during mobility- related activities of daily living (Hesse et al. 2013). Improved gait quality may help re-learn walking and performing mobility-related activities (Hesse et al. 2013). Fur- thermore, it promotes restoration of activity. The results of the gait analysis are con- sistent with a more secure and dynamic gait; there was also facilitation of the knee extensor on the affected side in some selected patients. (Hesse et al. 2009)						
References of summarized studies	Hesse, S., Bardeleben, A., Rembitzki, I., Werner, C. (2009). Klinische und gang- analytische Befunde zur Schulterorthese Omo Neurexa. Clinical and Gait Analysis Data on Shoulder Orthosis Omo Neurexa. <i>Orthopädie-Technik</i> , 3: 177–181.						
	Hesse, S., Herrmann, C., Bardeleben, A., Holzgraefe, M., Werner, C., Wingen- dorf, I., Kirker, S. (2013). A new orthosis for subluxed, flaccid shoulder after stroke facilitates gait symmetry: A preliminary study. <i>Journal of Rehabilitation Med- icine</i> , 45 (7): 623–629. DOI: 10.2340/16501977-1172						

Other References


Jonsdottir, J., Cattaneo, D., Regola, A., Crippa, A., Recalcati, M., Rabuffetti, M., ... & Casiraghi, A. (2007). Concepts of motor learning applied to a rehabilitation protocol using biofeedback to improve gait in a chronic stroke patient: an AB system study with multiple gait analyses. *Neurorehabilitation and neural repair*, 21(2):190-194.

X-Ray

Major Findings

With Omo Neurexa compared to no orthotic treatment:

- → The distance between the point of the acromion and a perpendicular vertical line through the central point of the humeral head decreased by a mean of 0.8 ± 0.6 cm (in 83% of radiographed patients (10 out of 12) = significant repositioning of the humeral head (Hesse et al. 2013)
- → In 70% of patients the shoulder joint space was reduced by an average of 2.5cm after the 4-week intervention (Hesse et al. 2009)
- → 42% of patients wore the orthosis because of a shoulder subluxation: in 60% of those, the gap between the acromion and humeral head was closed and in 40% the gap was reduced after the 4-week intervention (Hesse et al. 2008)



Omo Neurexa improved the position of the humeral head

A) X-ray image of subluxated shoulder: Distance = gap between the point of the acromion and a perpendicular vertical line through the central point of the humeral head (Hesse et al. 2013); B) After 4-week intervention with Omo Neurexa the position of the humeral head could be improved, shown is the average subluxation gap (Hesse et al. 2009).

Clinical Relevance

"Stroke is the most frequent cause of permanent impairment in the industrialized world (Hesse et al. 2009)." In Germany approximately 180 persons per 100,000 suffer from stroke annually (Kolominsky-Rabas et al. 2006). A significant proportion of stroke survivors will experience neurologic squeal and pain, with the hemiplegic shoulder pain being most common with 15-84% of patients (Andersen et al. 1995, Barlak et al. 2009, Bowsher 1995, Kong et al. 2004, Leijon et al. 1998, Ratnasabapathy et al. 2003, Van Ouwenaller et al. 1986, Zorowitz et al. 1996). In the later phases of rehabilitation, a shoulder-hand syndrome may develop which is characterized by pain, edema and a restricted flexibility of shoulder and hand (Hesse et al. 2008).

The etiology of the painful shoulder syndrome (PSS) has been ascribed to the biomechanical compromise of the post-stroke glenohumeral joint, subluxation due to paresis of the shoulder girdle, shoulder spasticity, rotator cuff tears, and a limited range of motion (ROM) of the shoulder (Davies 1990, Paci et al. 2007, Vuagnat & Chantraine 2003). In early rehabilitation, a flaccid, rather than a spastic, type of PSS predominates, mainly characterized by paresis of the shoulder girdle, with shoulder subluxation, shoulder micro trauma and soft tissue inflammation (Braus et al. 1994, Hesse et al. 1992). When the patient raises the arm, the humeral head bumps against the acromion and causes micro trauma and soft tissue inflammation. It is the current understanding that this is an essential factor in the pathogenesis of the flaccid form of the painful shoulder. (Braus et al. 1994) The Omo Neurexa aims at repositioning the subluxated shoulder joint in the right position and thus reducing pain and improving gait. Three studies evaluated the effectiveness of the Omo Neurexa: **Summary** A conventional anterior-posterior X-ray of the affected shoulder with and without the Omo Neurexa was carried out, while the patient was standing. Two experienced radiologists independently measured to what extent the orthosis repositioned the shoulder head vertically. Two reference points were identified: the most inferolateral point of the acromion and the apex of the humeral head. A line was drawn between these two points, and the distance was measured. This X-ray examination revealed that the orthosis repositioned the humeral head in the vertical direction to a relevant extent. A repositioning effect was reported in 83.3% of patients (Hesse et al. 2013). A closing of the subluxation gap was also observed in 60% of patients in the study of Hesse et al. (2008). In the remaining 40% of patients included in this study, a reduction of the subluxation gap was observed. Hesse et al. (2009) reported a mean reduction in joint space of 2.5cm. Furthermore 45-86% of patients reported a reduction of shoulder pain due to wearing the Omo Neurexa (Hesse et al. 2008, Hesse et al. 2009, Hesse et al. 2013). Hesse, S., Bardeleben, A., Grunden, J., Rembitzki, I., Werner, C. (2008). Vorstel-**References of** lung einer neuen Schulterorthese zur Behandlung der schmerzhaften Schulter von summarized studies hochparetischen Patienten in der Frührehabilitation. Neurologie & Rehabilitation, 14 (2): 91-94. Hesse, S., Bardeleben, A., Rembitzki, I., Werner, C. (2009). Klinische und ganganalytische Befunde zur Schulterorthese Omo Neurexa. Clinical and Gait Analysis Data on Shoulder Orthosis Omo Neurexa. Orthopädie-Technik, 3: 177-181. Hesse, S., Herrmann, C., Bardeleben, A., Holzgraefe, M., Werner, C., Wingendorf, I., Kirker, S. (2013). A new orthosis for subluxed, flaccid shoulder after stroke facilitates gait symmetry: A preliminary study. Journal of Rehabilitation Medicine, 45 (7): 623-629. DOI: 10.2340/16501977-1172

Other References	Andersen, G., Vestergaard, K., Ingeman-Nielsen, M., Jensen, T. S. (1995). Inci- dence of central post-stroke pain. <i>Pain</i> , 61:177-86.
	Barlak, A., Unsal, S., Kaya, K., Sahin-Onat, S., & Ozel, S. (2009). Poststroke shoulder pain in Turkish stroke patients: relationship with clinical factors and func- tional outcomes. <i>International Journal of Rehabilitation Research</i> , 32(4):309-315.
	Bowsher, D. (1995). The management of central post-stroke pain. <i>Postgraduate Medical Journal</i> , 71:598-604
	Braus, D.F., Krauss, J.K., Strobel, J. (1994). The shoulder-hand syndrome after stroke: a prospective clinical trial. <i>Annals of Neurology</i> , 36:728–733.
	Davies, P.M. (1990). Right in the middle, selective trunk activity in the treatment of adult hemiplegia. Berlin: Springer-Verlag.
	Hesse, S., Friedrich, H., Domasch, C., Mauritz, K. H. (1992). Botulinum toxin ther- apy for upper limb flexor spasticity: preliminary results. <i>J Rehab Sci</i> , 5:98–101.
	Kolominsky-Rabas, P. L., Heuschmann, P. U., Marschall, D., Emmert, M., Baltzer, N., Neundörfer, B., Schöffski, O., Krobot, K. J. (2006). Lifetime cost of ischaemic stroke in Germany: results and national projections from a population-based stroke registry: the Erlangen Stroke Project. <i>Stroke</i> , 37:1179-1183.
	Kong, K. H., Woon, V. C., & Yang, S. Y. (2004). Prevalence of chronic pain and its impact on health-related quality of life in stroke survivors. <i>Archives of physical</i> <i>medicine and rehabilitation</i> , 85(1):35-40.
	Leijon, G., Boivie, J., Johannson, I. (1989). Central post-stroke pain - neurological symptoms and pain characteristics. <i>Pain</i> , 36:13-25.
	Paci, M., Nannetti, L., Taiti, P., Baccini, M., Rinaldi, L. (2007). Shoulder subluxa- tion after stroke: relationships with pain and motor recovery. <i>Physiotherapy Re-</i> search International, 12:95–104.
	Ratnasabapathy, Y., Broad, J., Baskett, J., Pledger, M., Marshall, J., Bonita, R.(2003). Shoulder pain in people with a stroke: a population-based study. <i>Clinical Rehabilitation</i> , 17(3):304-311.
	Van Ouwenaller, C., Laplace, P. M. & Chantraine, A. (1986). Painful shoulder in hemiplegia. <i>Archives of physical medicine and rehabilitation</i> , 67:23–26.
	Vuagnat, H. & Chantraine, A. (2003). Shoulder pain in hemiplegia revisited: contri- bution of functional electrical stimulation and other therapies. <i>Journal of Rehabili-</i> <i>tation Medicine</i> , 35:49-54.
	Zorowitz, R. D., Hughes, M. B., Idank, D., Ikai, T., & Johnston, M. V. (1996). Shoulder pain and subluxation after stroke: correlation or coincidence?. <i>American</i> <i>Journal of Occupational Therapy</i> , 50(3):194-201.
	▲ Back to overview table

EMG (Electromyographic) examination

Major Findings
 With Omo Neurexa compared to no orthotic treatment:
 Significantly more symmetric gait (Hesse et al. 2013)


 Prolonged hemiparetic side stance phase

 Higher and more appropriately timed muscle activity of the paretic quadriceps muscle

 Vastus lateralis muscle:

- 67% of patients had a more normal phasic pattern of activation in early stance phase (Hesse et al. 2013)
- Vastus medialis and biceps femoris muscles:
 75% of patients had a more normal phasic pattern of activation in early stance phase (Hesse et al. 2013)
- Gluteus medialis muscle:
 42% of patients showed more muscle activity during the early stance phase (Hesse et al. 2013)
- Quadriceps femoris muscle:
 40% of patients showed a more pronounced activity and showed an earlier onset of activity during the stance phase (Hesse et al. 2009)

There is more pronounced and more appropriately timed muscle activation when walking with Omo Neurexa



Raw and averaged and normalized activity of the affected Vastus lateralis muscle of a hemiparetic patient when walking without (top figure) and with Omo Neurexa (lower figure). (Hesse et al. 2013)


Clinical Relevance A myoelectric signal, or electromyogram (EMG), is the electrical manifestation of a muscle contraction. EMG is used as a diagnostic tool for identifying neuromuscular diseases, or as a research tool for studying kinesiology and disorders of motor control. It is recorded to detect and analyze the voluntary muscle activation in functional movements. With this method, the following questions can be answered: Is the muscle active? Is the muscle more / less active? When is the muscle active? Furthermore, the question of muscle coordination can be answered (symmetrical innervation of synergists, appropriate co-innervation of antagonists). (Konrad 2005)

At rest, muscle tissue is normally electrically inactive. After the electrical activity, the electromyograph should not detect any abnormal spontaneous activity. When the muscle contracts voluntarily, action potentials begin to appear. As the force of the

	muscle contraction increases, more and more muscle fibers produce action poten- tials. EMG findings vary with the type of disorder. Interpreting EMG findings is usu- ally best done in a context of physical examination of the patient, and in conjunction with the results of other relevant diagnostic procedures. (Konrad 2005) EMG provides easy access to physiological processes that cause the muscle to generate force, produce movement, and accomplish the countless functions that allow us to interact with the world around us (de Luca 1997).
Summary	Two studies evaluated the effectiveness of the Omo Neurexa:
	Electromyographic activity was detected by self-adhesive surface electrodes, which were attached 2 cm apart on the muscle bellies. On each subject's affected side, recordings were obtained for the following muscles: tibialis anterior, medial head of the gastrocnemius, vastus lateralis, vastus medialis, rectus femoris, biceps femoris, gluteus medius and erector spinae.
	The qualitative analysis of the dynamic EMG revealed a more normal phasic pattern of activation of the vastus lateralis muscle in the early stance phase. For the vastus medialis and biceps femoris, the same pattern change was seen. The gluteus medi- us muscle became more active in the early stance phase. The shank muscles and the erector spinae revealed no discernible alterations of their muscle activation pat- terns. (Hesse et al. 2013)
	One aspect observed when walking with the Omo Neurexa was a more symmetric and dynamic gait pattern (Hesse et al. 2009, Hesse et al. 2013) and an improve- ment in activity level and performance during mobility related activities of daily living (Hesse et al. 2013).
	This improved gait quality may help in re-learn walking and performing mobility- related activities (Hesse et al. 2013).
	Furthermore, it promotes restoration of activity. The results of the gait analysis are consistent with a more secure and dynamic gait; there was also facilitation of the knee extensor on the affected side in some selected patients. (Hesse et al. 2009)
References of summarized studies	Hesse, S., Bardeleben, A., Rembitzki, I., Werner, C. (2009). Klinische und gang- analytische Befunde zur Schulterorthese Omo Neurexa. Clinical and Gait Analysis Data on Shoulder Orthosis Omo Neurexa. <i>Orthopädie-Technik</i> , 3: 177–181.
	Hesse, S., Herrmann, C., Bardeleben, A., Holzgraefe, M., Werner, C., Wingen- dorf, I., Kirker, S. (2013). A new orthosis for subluxed, flaccid shoulder after stroke facilitates gait symmetry: A preliminary study. <i>Journal of Rehabilitation Med- icine</i> , 45 (7): 623–629. DOI: 10.2340/16501977-1172
Other References	De Luca, C. J. (1997). The use of surface electromyography in biomechanics. <i>Jour-nal of applied biomechanics</i> , 13:135-163.
	Konrad, P. (2005). EMG-Fibel. ABC of EMG. A Practical Introduction to Kinesiolog- ical Electromyography. Noraxon Inc. USA.

Functional tests

With Omo Neurexa compared to no orthotic treatment:					
 → The muscle strength (MRC score) increased significantly (Hesse et al. 2013) 30% of patients showed an increase in shoulder strength (Hesse et al. 2009) 40% of patients showed an increase in elbow strength (Hesse et al. 2009) 					
 → Minor changes in muscle tone assessed on Ashworth scale 30% of patients showed a decreased Ashworth score (reduction of spasticity) (Hesse et al. 2009) 40% of patients showed an increase in the Ashworth score (development of flexor spasticity) (Hesse et al. 2009) The muscle tone on Ashworth scale remains constant (Hesse et al. 2013) → Tendency towards an increased shoulder Range of Motion (RoM) (Hesse et al. 2013) 30% of patients showed an improvement in passive RoM (Hesse et al. 2009) 10% of patients showed a deterioration in passive RoM (Hesse et al. 2009) 					
With Omo Neurexa improvements in functional tests was ob- served					



(Hesse et al. 2009)

Clinical Relevance

"Stroke is the most frequent cause of permanent impairment in the industrialized world (Hesse et al. 2009)." Fifteen million people suffer from stroke every year worldwide, five million die and another five million are left with permanent disability (WHO report 2009). An ischemic stroke may lead to a hemiparesis, accompanied by abnormalities of muscle tone (identified as spastic hypertonia or spasticity), muscle weakness and impaired muscular coordination (movement dysfunction) (Dewald et al. 2001, Sabut et al. 2011).

	Muscle weakness is a significant consequence of stroke. Reduction of muscle strength is due to the combined effects of the upper motor neuron lesion and secondary adaptations due to denervation, disuse and inactivity and, in some individuals, the effects of aging. Muscle strength is directly related to functional performance. (Ng & Shepherd 2013)
	The major clinical problems related to spasticity after stroke are mobility decrease and hypertonus, resulting in a range of motion (RoM) restriction, abnormal pos- tures, pain and fixed contractures, with poor response to physiotherapy (Reiter et al. 1998).
	The recovery of upper limb function is of great importance in improving the patients' quality of life and helping them maximize their independence (Kwakkel et al. 2003). Rehabilitation can help to ease symptoms, and restore upper limb function. Assessment of recovery is an important aspect of any rehabilitation program. (Bai et al. 2014)
	The Ashworth scale is the most popular clinical measure of muscle spasticity and resistance to passive movement (Ansari et al. 2009).
	The Medical Research Council (MRC) Scale for muscle strength grades the muscle strength from 0= "no movement is observed" to 5= "muscle contract normally against full resistance". (Paternostro-Sluga et al. 2008)
Summary	Two studies evaluated the effectiveness of the Omo Neurexa:
	The muscle strength evaluated with the MRC score could be increased in the shoulder and elbow muscles in 30-40% of patients as well as the range of motion in the shoulder joint. Accordingly, the muscle tone, assessed with the Ashworth scale remains constant (Hesse et al. 2009, Hesse et al. 2013).
References of summarized studies	Hesse, S., Bardeleben, A., Rembitzki, I., Werner, C. (2009). Klinische und gang- analytische Befunde zur Schulterorthese Omo Neurexa. Clinical and Gait Analysis Data on Shoulder Orthosis Omo Neurexa. <i>Orthopädie-Technik</i> , 3: 177–181.
	Hesse, S., Herrmann, C., Bardeleben, A., Holzgraefe, M., Werner, C., Wingen- dorf, I., Kirker, S. (2013). A new orthosis for subluxed, flaccid shoulder after stroke facilitates gait symmetry: A preliminary study. <i>Journal of Rehabilitation Med-</i> <i>icine</i> , 45 (7): 623–629. DOI: 10.2340/16501977-1172
Other References	Ansari, N. N., Naghdi, S., Arab, T. K., & Jalaie, S. (2008). The interrater and in- trarater reliability of the Modified Ashworth Scale in the assessment of muscle spasticity: limb and muscle group effect. <i>NeuroRehabilitation</i> , 23(3):231-237.
	Bai, L., Pepper, M.G., Yan, Y., Spurgeon, S.K., Sakel, M., Phillips, M., (2014). Quantitative Assessment of Upper Limb Motion in Neurorehabilitation Utilizing In- ertial Sensors. TNSRE-2013-00273.R2. https://kar.kent.ac.uk/47726/1/TNSRE- 2013-00273%20R2-Final_Version.pdf
	Dewald, J. P., Sheshadri, V., Dawson, M. L., & Beer, R. F. (2001). Upper-limb dis- coordination in hemiparetic stroke: implications for neurorehabilitation. <i>Topics in</i> <i>stroke rehabilitation</i> , 8(1):1-12.
	Kwakkel, G., Kollen, B. J., van der Grond, J., & Prevo, A. J. (2003). Probability of regaining dexterity in the flaccid upper limb impact of severity of paresis and time since onset in acute stroke. <i>Stroke</i> , 34(9):2181-2186.

Ng, S. S., & Shepherd, R. B. (2013). Weakness in patients with stroke: implications for strength training in neurorehabilitation. *Physical Therapy Reviews*.

- Paternostro-Sluga, T., Grim-Stieger, M., Posch, M., Schuhfried, O., Vacariu, G., Mittermaier, C., ... & Fialka-Moser, V. (2008). Reliability and validity of the Medical Research Council (MRC) scale and a modified scale for testing muscle strength in patients with radial palsy. *Journal of rehabilitation medicine*, 40(8):665-671.
- Reiter, F., Danni, M., Lagalla, G., Ceravolo, G., & Provinciali, L. (1998). Low-dose botulinum toxin with ankle taping for the treatment of spastic equinovarus foot after stroke. *Archives of physical medicine and rehabilitation*, 79(5):532-535.
- Sabut, S. K., Sikdar, C., Kumar, R., & Mahadevappa, M. (2011). Functional electrical stimulation of dorsiflexor muscle: effects on dorsiflexor strength, plantarflexor spasticity, and motor recovery in stroke patients. *NeuroRehabilitation*, 29(4):393-400.
- WHO report. Cardiovascular diseases: Facts about cardio- vascular diseases, 2009. [Online] http://www.who.int/mediacentre/factsheets/fs317/en/index.html.

Clinical effects

Major Findings


With Omo Neurexa compared to no orthotic treatment:

Patient-reported

- → Patients reported a positive effect of Omo Neurexa in terms of pain reduction (45%), activity level (55%) and performance of mobility related ADL's (58%) (Hesse et al. 2013)
- → 50% of patients reported a reduction of shoulder pain and another 50% reported on no change in the pain situation (Hesse et al. 2009)
- → 58% of patients reported shoulder pain at the beginning of the intervention phase: 86% of those patients reported a relevant reduction of shoulder pain due to wearing the orthosis (Hesse et al. 2008)
- → Protection of the paretic arm leads to a better concentration on gait rehabilitation (Hesse et al. 2008)

Therapist-reported

→ Therapists reported a positive effect of Omo Neurexa in terms of activity level (70%) and performance of mobility-related ADL's (55%) (Hesse et al. 2013)



Omo Neurexa improved the ability of the patients to participate in daily activities

(Hesse et al. 2013)

Clinical Relevance

The annual incidence of stroke in the industrialized world is approximately 180 per 100,000 inhabitants, and it is the most common cause of permanent disability (Hesse et al. 1995, Kolominsky-Rabas et al. 2006). A significant proportion of stroke survivors will experience neurologic squeal and complications. Pain is a common complication after a stroke. The most frequent pain condition is the hemiplegic shoulder pain. (Kong et al. 2004)

	 The painful shoulder syndrome (PSS) occurs in 15–84% of subacute stroke survivors, and it is associated with an extended length of stay and a poorer rehabilitation outcome (Andersen et al. 1995, Barlak et al. 2009, Bowsher 1995, Leijon et al. 1998, Ratnasabapathy et al. 2003, Van Ouwenaller et al. 1986, Zorowitz et al. 1996). It leads to a limitation in performing ADLs, participation and rehabilitation activities. All this leads to a poor functionality. (Lindgren 2013, Murie-Fernández et al. 2012) Activity and mobility are assessed to get an insight into general independence of the patient. An increased grade of mobility is crucial to reach a satisfying quality of life. Activities of daily living (ADLs) include self-care activities as functional mobility, dressing, eating and personal hygiene as well as activities to live independently in a
	community.
Summary	Three studies evaluated the effectiveness of the Omo Neurexa:
	A reduction in shoulder pain due to wearing the Omo Neurexa was reported by 45%-86% of patients in all three studies that evaluated the Omo Neurexa (Hesse et al. 2008, Hesse et al. 2009, Hesse et al. 2013).
	Another aspect observed when wearing the Omo Neurexa was an improvement in activity level and performance during mobility related activities of daily living (Hesse et al. 2013).
	This might be due to the finding that the subluxation gap could be reduced or even closed with Omo Neurexa in the majority of patients in all three studies (Hesse et al. 2008, Hesse et al. 2009, Hesse et al. 2013).
References of summarized studies	Hesse, S., Bardeleben, A., Grunden, J., Rembitzki, I., Werner, C. (2008). Vorstel- lung einer neuen Schulterorthese zur Behandlung der schmerzhaften Schulter von hochparetischen Patienten in der Frührehabilitation. <i>Neurologie & Rehabilitation</i> , 14 (2): 91–94.
	Hesse, S., Bardeleben, A., Rembitzki, I., Werner, C. (2009). Klinische und gang- analytische Befunde zur Schulterorthese Omo Neurexa. Clinical and Gait Analysis Data on Shoulder Orthosis Omo Neurexa. <i>Orthopädie-Technik</i> , 3: 177–181.
	Hesse, S., Herrmann, C., Bardeleben, A., Holzgraefe, M., Werner, C., Wingen- dorf, I., Kirker, S. (2013). A new orthosis for subluxed, flaccid shoulder after stroke facilitates gait symmetry: A preliminary study. <i>Journal of Rehabilitation Med- icine</i> , 45 (7): 623–629. DOI: 10.2340/16501977-1172
Other References	Andersen, G., Vestergaard, K., Ingeman-Nielsen, M., Jensen, T. S. (1995). Inci- dence of central post-stroke pain. <i>Pain</i> , 61:177-86.
	Barlak, A., Unsal, S., Kaya, K., Sahin-Onat, S., & Ozel, S. (2009). Poststroke shoulder pain in Turkish stroke patients: relationship with clinical factors and func- tional outcomes. <i>International Journal of Rehabilitation Research</i> , 32(4):309-315.
	Bowsher, D. (1995). The management of central post-stroke pain. <i>Postgraduate Medical Journal</i> , 71:598-604
	Hesse, S., Jahnke, M. T., Ehret, R., Mauritz, K. H. (1995). Shoulder-hand syn- drome in hemiplegic patients: temperature, sympathic skin responses and nerve conduction velocities. <i>J Neurol Rehab</i> , 9:229-233

- Kolominsky-Rabas, P. L., Heuschmann, P. U., Marschall, D., Emmert, M., Baltzer, N., Neundörfer, B., Schöffski, O., Krobot, K. J. (2006). Lifetime cost of ischaemic stroke in Germany: results and national projections from a population-based stroke registry: the Erlangen Stroke Project. *Stroke*, 37:1179-1183.
- Kong, K. H., Woon, V. C., & Yang, S. Y. (2004). Prevalence of chronic pain and its impact on health-related quality of life in stroke survivors. *Archives of physical medicine and rehabilitation*, 85(1):35-40.
- Murie-Fernández, M., Iragui, M. C., Gnanakumar, V., Meyer, M., Foley, N., & Teasell, R. (2012). Painful hemiplegic shoulder in stroke patients: causes and management. *Neurología (English Edition)*, 27(4):234-244.
- Leijon, G., Boivie, J., Johannson, I. (1989). Central post-stroke pain neurological symptoms and pain characteristics. *Pain*, 36:13-25.
- Lindgren, I. (2013). Shoulder pain after stroke Prevalence, contributing factors and consequences in daily life *Doctoral Dissertation*, Lund University.
- Ratnasabapathy, Y., Broad, J., Baskett, J., Pledger, M., Marshall, J., Bonita, R. (2003). Shoulder pain in people with a stroke: a population-based study. *Clinical Rehabilitation*, 17(3):304-311.
- Van Ouwenaller, C., Laplace, P. M. & Chantraine, A. (1986). Painful shoulder in hemiplegia. *Archives of Physical Medicine and Rehabilitation*; 67:23–26.
- Vuagnat, H. & Chantraine, A. (2003). Shoulder pain in hemiplegia revisited: contribution of functional electrical stimulation and other therapies. *Journal of Rehabilitation Medicine*, 35:49-54.

Zorowitz, R. D., Hughes, M. B., Idank, D., Ikai, T., & Johnston, M. V. (1996). Shoulder pain and subluxation after stroke: correlation or coincidence?. *American Journal of Occupational Therapy*, 50(3):194-201.

<u>A Back to overview table</u>

Satisfaction

Major Findings	With Omo Neurexa compared to no orthotic treatment:						
	Wearing comfort: Patient-reported						
	→ Patients perceived the material of the orthosis as comfortable on the skin Furthermore, no pressure sores, chafe marks or other adverse reactions (espe- cially no relevant increase in spasticity at the upper extremity, no stiffening of the shoulder, no excessive swelling of the hand, no skin irritations or redness) were seen (Hesse et al. 2008)						
	→ 76.9% of patients reported good wearing comfort (Hesse et al. 2009)						
	→ 80% of patients had a score ≥ 7 on VAS (visual analog scale; 0= very bad, 10= excellent), indicating good wearing comfort (Hesse et al. 2013)						
	Wearing Comfort: Therapist-reported						
	→ 73% of the therapists rated wearing comfort with a VAS score ≥ 7, indicat- ing good wearing comfort (Hesse et al. 2013)						
	Odour nuisance: Patient-reported						
	→ Minimal odour nuisance due to transpiration (Hesse et al. 2008)						
	 → 76.9% of patients had only minimal odour build-up (Hesse et al. 2009) → 85% of patients had a score ≤ 3 on VAS (0= absent, 10= intolerable), indicating tolerable odour nuisance (Hesse et al. 2013) 						
	Odour nuisance: Therapist-reported → 83% of the therapists rated odour with a VAS score ≤ 3, indicating tolerable odour nuisance (Hesse et al. 2013)						
	Omo Neurexa showed good wearing comfort and minimal odour nuisance						
	Note that the second se						

wearing comfort

odour

⁽Hesse et al. 2013)

Clinical Relevance	Satisfaction can be measured to determine the general well-being of a person and the fulfillment of his expectations to the medical device. It is a very meaningful pa- rameter to investigate since it has a direct impact on the patients well-being and compliance. It is influenced by other categories and can therefore be seen as a summary of possible pain reduction and better performance of ADLs.					
	Satisfaction is also correlated with the usage of the medical device. Studies on the non-use of devices suggest that, on average, a third of all devices provided are not used (Scherer 2002). Reasons for non-use involve lack of consumer involvement, inadequate performance of the product, failure of the product to improve function, and difficulty in operating the product (Batavia & Hammer 1990, Wielandt & Strong 2000). Obtaining user perspectives and satisfaction is therefore fundamental.					
Summary	The satisfaction with the Omo Neurexa was assessed in all three studies:					
	At the end of the intervention, the patients (Hesse et al. 2008, Hesse et al. 2009, Hesse et al. 2013) and the attending physiotherapists (Hesse et al. 2013) rated the wearing comfort and the odour nuisance using a visual analog scale (0-10). The physiotherapists based their assessment on the observation of patients during treatment.					
	The majority of patients tolerated the orthosis well. In all referenced studies, pa- tients reported a good wearing comfort of the orthoses and only minimal odour nui- sance (Hesse et al. 2008, Hesse et al. 2009, Hesse et al. 2013). The physiothera- pists reported that the orthosis helped improve walking performance and other mobility-related tasks (Hesse et al. 2013). Furthermore 45-86% of patients reported a reduction of shoulder pain due to wearing the Omo Neurexa (Hesse et al. 2008, Hesse et al. 2009, Hesse et al. 2013).					
	"The well-tolerated shoulder orthosis offered a good fit, and ease of performing activities" (Hesse et al. 2013)					
References of summarized studies	Hesse, S., Bardeleben, A., Grunden, J., Rembitzki, I., Werner, C. (2008). Vorstel- lung einer neuen Schulterorthese zur Behandlung der schmerzhaften Schulter von hochparetischen Patienten in der Frührehabilitation. <i>Neurologie & Rehabilitation</i> , 14 (2): 91–94.					
	Hesse, S., Bardeleben, A., Rembitzki, I., Werner, C. (2009). Klinische und gang- analytische Befunde zur Schulterorthese Omo Neurexa. Clinical and Gait Analysis Data on Shoulder Orthosis Omo Neurexa. <i>Orthopädie-Technik</i> , 3: 177–181.					
	Hesse, S., Herrmann, C., Bardeleben, A., Holzgraefe, M., Werner, C., Wingen- dorf, I., Kirker, S. (2013). A new orthosis for subluxed, flaccid shoulder after stroke facilitates gait symmetry: A preliminary study. <i>Journal of Rehabilitation Med- icine</i> , 45 (7): 623–629. DOI: 10.2340/16501977-1172					
Other References	Batavia, A. I., & Hammer, G. S. (1990). Toward the development of consumer- based criteria for the evaluation of assistive devices. <i>Journal of rehabilitation re-</i> <i>search and development</i> , 27(4):425-436.					
	Scherer, M. J. (2002). The change in emphasis from people to person: introduction to the special issue on Assistive Technology. <i>Disability and rehabilitation</i> , 24(1-3):1-4.					

Wielandt, T., & Strong, J. (2000). Compliance with prescribed adaptive equipment: a literature review. *The British Journal of Occupational Therapy*, 63(2):65-75.

<u> A Back to overview table</u>

3 Summaries of individual studies

On the following pages you find summaries of studies that researched Omo Neurexa. You find detailed information about the study design, methods applied, results and major findings of the study. At the end of each summary you also can read the original study authors' conclusions.

R	ef	0	r	0	n	C	0
	CI	6		-			-

Hesse, S., Herrmann, C., Bardeleben, A., Holzgraefe, M., Werner, C., Wingendorf, I., & Kirker, S. G. B.

Medical Park Berlin Humboldtmühle, Neurological Rehabilitation, Charité - University Medicine Berlin, Germany.

A new orthosis for subluxed, flaccid shoulder after stroke facilitates gait symmetry: a preliminary study.


Journal of Rehabilitation Medicine 2013; 45 (7): 623-629.

DOI: 10.2340/16501977-1172.

Products	Omo Neurexa				
Major Findings	With Omo Neurexa compared to no orthotic treatment:				
	ightarrow In 83.3% of radiographed patients: repositioning of the humeral head				
	\rightarrow 45% of patients reported a reduction of pain				
	→ Improved patient- and therapist-reported activity level and performance in mobility related activities of daily living				
	 → Significantly more symmetric gait Prolonged hemiparetic side stance phase Higher and more appropriately timed muscle activity of the paretic guadriceps muscle 				

\rightarrow Very good wearing comfort and minimal odour nuisance

Omo Neurexa improved the ability of the patient to participate in daily activities



Population	Subjects:	40 patients (27 men, 13 women)
	Mean age:	60.3 ± 16.7 years
	Time since stroke:	6.3 ± 3.3 weeks
	Inclusion criteria:	- first-ever supratentorial stroke
		- hemiparesis
		- participation in a comprehensive in-patient
		rehabilitation programme
		- non-functional upper extremity
		- subluxated shoulder
		 pain in the effected shoulder, reported by the patient and/or therapist
		- ability to walk at least 20 m
		- no relevant impairment of pain sensation in the arm

Before-and-after study with 4-week follow-up (with Omo Neurexa compared to no orthotic treatment):



Radiography of the shoulder and instrumented gait analysis with dynamic EMG recording with and without the orthosis was performed in 12 of the 40 patients in one trial site after at least one week of wearing the orthosis.

Functions and Activities						Participation
	Biomechanics – Gait analysis	X-Ray	EMG	Functional tests	Clinical effects	Satisfaction
Category	Outcomes			Results for Omo Neurexa		
Biomechanics – Gait analysis	Relative stance phase dura- tion (affected leg)		Significant increase by 7.5% (from 58.8% to 63.2%)			++
	Stance sym	Stance symmetry ratio		icant increase by 6.9 0.87 to 0.93)	9%	++
	Walking vel	Walking velocity		No significant differences		
	Stride lengt	Stride length Cadence		No significant differences No significant differences		
	Cadence					
	Relative do	uble support ratio	No sig	nificant differences		0
	Swing symr	metry ratio	No sig	nificant differences		0

Study Design

Functions and Activit	ties				Participation
	Biomechanics – X-Ray Gait analysis	EMG	Functional tests	Clinical effects	Satisfaction
Category	Outcomes	Result	s for Omo Neurexa		Sig.*
X-Ray	Distance between the of the acromion and a pendicular vertical through the central point the humeral head	per- cm (in line of 12)	83% of radiographe	ed patients (10	
EMG	Lateral vastus muscle		of patients had a m of activation in early atients)		
	Medial vastus muscle / b ceps femoris muscle	pattern	of patients had a m of activation in early re mentioned 8 patien	stance phase (6	
	Medial gluteus muscle		f patients showed m the early stance pha		-
	Shank muscles / erector spinae muscle	No cha	nges in muscle activa	tion pattern	n.a.
Functional tests	Shoulder ROM [Fugl-Meyer-score]		ncrease: 2.2 ± 3.2 cy towards an increa	sed shoulder R0	+ DM
	Muscle strength sum sco [Medical Research Cour (MRC) grades]		ncrease: 6.2 ± 6.0		++
	Muscle tone	Remair	ned constant		0
Clinical effects	Patient: results for the a bility-related activities of		pain, activity level ar	d performance	of mo-
		Positive effe	ect No change	e Negativ	e effect
	Pain	45%	47.5%	7.5	6%
	Activity level	55%	42.5%	2.5	6%
	Performance of mobil- ity related ADL	57.5%	37.5%	59	%
	Therapist: results for the related activities of daily			erformance of m	obility-
		Positive ef	fect No chang	le Negati	ve effect
	Activity level	70%	27.5%	2.	5%
	Performance of mobili- ty related ADL	55%	32.5%	12	.5%
Satisfaction	Wearing comfort 0 = very bad		80% of patients ha good wearing comfor		indicating a
	10 = excellent	-	in 73% of patients t comfort with a score ing comfort	-	-

Functions and Activ	ties					Participation	
	Biomechanics – X Gait analysis	(-Ray	EMG	Functional tests	Clinical effects	Satisfaction	
0 0	Outcomes		Results for Omo Neurexa			Sig.*	
	Odour 0 = absent		Patients:	 85% of patients had a score <3, indicating tolerable odour nuisance ts: in 83% of patients the therapists rated odour wi a score <3, indicating a tolerable odour nuisance 			
	10 = intolerable	.0 = intolerable Th					
	Wearing time p	ber day	Mean: 6.8 ±	1.8 hours			

* no difference (0), positive trend (+), negative trend (-), significant (++/--), not applicable (n.a.)

Author's Conclusion

"In conclusion, the well-tolerated shoulder orthosis improved gait quality and repositioned the subluxated humeral head, offered a good fit, eased performing activities, but did not help reduce pain. The orthosis may be a clinical option for wheelchairbound stroke subjects with PSS when re-learning walking and performing mobilityrelated activities. This preliminary study does not warrant any definite conclusions on the effectiveness of the orthosis; further studies are needed to compare its effect with other models." (Hesse et al. 2013)

Hesse, S., Bardeleben, A., Rembitzki, I., & Werner, C.

Medical Park Berlin Humboldtmühle, Neurological Rehabilitation, Charité - University Medicine Berlin, Germany.

Clinical and Gait Analysis Data on the Shoulder Orthosis Omo Neurexa

Klinische und ganganalytische Befunde zur Schulterorthese Omo Neurexa

Orthopädie-Technik 2009; 3: 177-181.

Products	Omo Neurexa						
Major Findings	With Omo Neurexa compared to no orthotic treatment:						
	ightarrow 50% of patients reported a relevant pain reduction						
	→ Decrease of the shoulder subluxation was observed						
	 → 70% of patients reported that they felt more secure during transfer tasks and mobility → More dynamic gait pattern → Good wearing comfort, minimal transpiration 						
	Omo Neurexa showed improvements in majority of categories assessed 8						
	7						
	6						
	5						

number of patients

4

3

2

1

0

shoulder

pain

use of the

arm in

everyday

activities

participation mobility in

everyday

activities

in physical

therapy

improvement

∎no change

performing participation

and mood

activities of


daily life

Population

Subjects:	13 patients** (10 men, 3 women) ** 3 patients stopped using the orthosis prematurely
Mean age:	61.7 ± 12 years
Mean interval since stroke	
(before the orthosis was prescribed):	8.3 ± 3.8 weeks
Inclusion criteria:	 shoulder pain or clinical signs of subluxation first-ever stroke with treatment in inpatient early rehabilitation non-functioning paretic upper extremity

Study Design

Pilot Study with a four-week-intervention



Gait analysis and measurement of EMG was performed with 10 patients with and without the orthosis.

Results

Functions and Activit	ies						Participation		
	Biomechanics – Gait analysis	X-Ray	EMG		Functional tests	Clinical effects	Satisfactio	on	
Category	Outc	omes		Resul	ts for Omo Neu	rexa**		Sig.*	
Biomechanics – Gait analysis		Relative double support phase			reduction: 17%			++	
	Stride	Stride length			Tendency towards a greater stride length			+	
	Cade	Cadence Gait speed Relative stance and swing periods			Tendency towards a lower cadence No significant differences			+	
	Gaits							0	
					No significant differences				
	Symn	netry quotients	S	No sig	nificant differenc	ces		0	
X-Ray	a pe line t		on and vertical central		reduction of 2.8 % of patients)	ōcm due to the	e orthosis	n.a.	

Functions and Activitie	es				Participatio	on
Biomechanics – Static measures	Biomechanics – X-Ray Gait analysis	EMG	Functional tests	Clinical effects	Satisfactio	on
Category	Outcomes	R	esults for Omo Neu	rexa**		Sig.*
EMG	Dynamic EMG		0% of patients show ctivity of the quadrice	•		n.a.
		a	0% of patients sho ctivity of the quadric g the stance phase			n.a.
Functional tests	Passive shoulder F	ROM 3	0% of patients show	ed an improvem	ent	n.a.
		1	0% of patients show	ed a deterioratio	n	n.a.
	MRC strength grad		0% of patients shov er strength	ved an increase	in shoul-	n.a.
			0% of patients show rength	ed an increase	in elbow	n.a.
	Ashworth score		0% of patients sho orth score (reductior		sed Ash-	n.a.
			0% of patients sho shworth score (devel)			n.a.
Clinical effects	Pain		0% of patients repor er pain	ted a reduction	of shoul-	n.a.
			0% of patients rep nchanged	orted shoulder	pain as	n.a.


* no difference (0), positive trend (+), negative trend (-), significant (++/--), not applicable (n.a.) ** results are valid for those 10 patients who finished the study

Category Outcomes		Results for Omo Neurexa***				
Satisfaction	Wearing comfort	76.9% of patients: good wearing comfort with only minimal odour build-up	n.a.			
		23.1% of patients stopped wearing the ortho- sis prematurely				

* no difference (0), positive trend (+), negative trend (-), significant (++/--), not applicable (n.a.) *** results are valid for all 13 patients who were included in the study

Author's Conclusion "In summary, the newly developed shoulder orthosis is an interesting component in the prevention and therapy of painful shoulder in severely paretic patients in multiprofessional early rehabilitation. Provided that the nursing staff is given extensive training, good fit, a high level of wearing comfort, and minimal amount of unpleasant odour can be ensured. The open study indicates that the orthosis reduces subluxation and promotes restoration of activity. The results of the gait analysis are consistent with a more secure and dynamic gait; there was also facilitation of the knee extensor on the affected side in some selected patients. A controlled study is indicated." (Hesse et al. 2009)

Hesse, S., Bardeleben, A., Grunden, J., Rembitzki, I., & Werner, C.								
Medical Park Berlin Humboldtmühle, Neurological Rehabilitation, Charité - Universi- ty Medicine Berlin, Germany. Presentation of a new shoulder orthosis for the treatment of a painful shoulder in highly paretic patients in the early phase of rehabilitation								
							(Vorstellung einer neuen Schulterorthese zur Behandlung der schmerzhaften	
Schulter von hochparetischen Patienten in der Frührehabilitation)								
Neurologie & Rehabilitation 2008; 14 (2): 89-92.								
Omo Neurexa								
With Omo Neurexa compared to no orthotic treatment:								
 58% of patients reported shoulder pain at the beginning of the intervention phase: → 86% of those patients reported a relevant reduction of shoulder pain due to wearing the orthosis 								
 42% of patients showed a subluxation of the shoulder at the beginning of the intervention phase: → In 40% of patients a reduction of the subluxation gap was observed after the time of intervention → In 60% of patients, the gap was closed after the time of intervention → 20% of patients developed a painful shoulder (PS) during the intervention period 								
Patients treated with Omo Neurexa suffer less pain								
90								
60								



Population	Subjects: Mean age: Indication:	12 patients (1 patient did not wear the orthosis for the who 4 weeks because of missing efficiency) n.a. hemiparetic patients in the early stages of rehabilitation: Patients did suffer from a subluxation of the shoulder or painful shoulder					
Study Design	Clinical experience						
			weeks ilitation unit				

Results

Functions and Activi	ties	Particip	ation
	Biomechanics – X-R Gait analysis	ay EMG Functional tests Clinical effects Satisfa	ction
Category	Outcomes	Results for Omo Neurexa	Sig.*
X-Ray	Shoulder subluxa- tion	42% of patients wore the orthosis because of a shoul- der subluxation	n.a.
		60% of patients: closing of the gap	n.a.
		40% of patients: reduction of the gap	n.a.
		20% of patients: development of shoulder pain	n.a.
Clinical effects	Shoulder Pain	59% of patients suffered from a painful shoulder	n.a.
		86% of patients reported a reduction of shoulder pain	n.a.
	Concentration	Protection of the paretic arm leads to a better concen- tration on gait rehabilitation	n.a.
Satisfaction	Wearing comfort	Patients perceived the material of the orthosis as com- fortable on the skin.	n.a.
		\rightarrow no pressure scores, chafe marks or other adverse reactions (especially no relevant increase of spasticity within the upper extremity, no stiffening of the shoulder, no excessive swelling of the hand, no skin irritations or redness)	
	Odour nuisance	Minimal odour nuisance due to transpiration	n.a.

"In conclusion the orthosis is an interesting option in the treatment and prevention **Author's Conclusion** of shoulder pain of the severely affected arm after stroke. Further studies are needed." (Hesse et al. 2008)

<u>A Back to overview table</u>

Copyright:

© 2014, Otto Bock HealthCare Products GmbH ("Otto Bock"), All Rights Reserved. This document contains copyrighted material. Wherever possible we give full recognition to the authors. We believe this constitutes a 'fair use' of any such copyrighted material according to Title 17 U.S.C. Section 107 of US Copyright Law. If you wish to use copyrighted material from this site for purposes of your own that go beyond 'fair use', you must obtain permission from the copyright owner. All trademarks, copyrights, or other intellectual property used or referenced herein are the property of their respective owners. The information presented here is in summary form only and intended to provide broad knowledge of products offered. You should consult your physician before purchasing any product(s). Otto Bock disclaims any liability related from medical decisions made based on this document.